Mental Health

argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia

First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease...

BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

ANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative...

Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

QHSLab, Inc. Projects a $7.5 Billion Addressable Market for its Integrated Service Program (ISP) Digital Health Solution Designed For Primary Care

This forecast is based on estimates generated through a recent pilot program and scaled through approximately 250,000 independent primary care...

error: Content is protected !!